Auf dieser Seite
HRTX Heron Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 10, 2026
$0,35
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$0,2652-Wochen-Tief
$1,5552-Wochen-Hoch
Marktkapitalisierung
$65M
P/E (TTM)
-1.9
EPS (TTM)
$-0.18
Umsatz (TTM)
$151M
Ihre Abzeichen
52W-Spanne
$0–$2
Analystenbewertung
HOLD
Kursziel
$7
P/E
-1.9
ROE
334.6%
Nettogewinnmarge
-22.5%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
HRTX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$0.35
Marktkapitalisierung
$65M
P/E (TTM)
-1.9
EPS (TTM)
$-0.18
Umsatz (TTM)
$151M
ROE (TTM)
334.6%
52W-Spanne
$0–$2
HRTX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 13. Januar 2014 | 1-for-20 | Umgekehrt |
| 25. Mai 2007 | 1-for-4 | Umgekehrt |
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$155M2016-12-31 → 2025-12-31
EPS$-0.122021-12-31 → 2025-12-31
Freier Cashflow$-28M2016-12-31 → 2025-12-31
Nettogewinnmarge-22.5%2016-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | HRTX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -1.95-Jahres-Durchschnitt ≈-7.1 | ≈-7.1 | · | · | |
| P/S | 0.45-Jahres-Durchschnitt ≈3.8 | ≈3.8 | 186.1 | Unterbewertet | |
| P/B (K/B) | 4.65-Jahres-Durchschnitt ≈7.3 | ≈7.3 | 1.3 | Überbewertet | |
| Price / FCF (Kurs / FCF) | -2.35-Jahres-Durchschnitt ≈-5.8 | ≈-5.8 | · | · | |
| Price / Cash Flow (Kurs / Cashflow) | -2.45-Jahres-Durchschnitt ≈-6.0 | ≈-6.0 | · | · | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 4.65-Jahres-Durchschnitt ≈17.0 | ≈17.0 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | HRTX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Bruttogewinnmarge (TTM) | 70.1%5-Jahres-Durchschnitt ≈65.1% | ≈65.1% | · | · | |
| Betriebsgewinnmarge (TTM) | -7.2%5-Jahres-Durchschnitt ≈-102.2% | ≈-102.2% | -2571.0% | Spitzenklasse | |
| EBITDA-Marge (TTM) | -5.8%5-Jahres-Durchschnitt ≈-99.9% | ≈-99.9% | -2571.0% | Spitzenklasse | |
| Nettogewinnmarge (TTM) | -22.5%5-Jahres-Durchschnitt ≈-106.8% | ≈-106.8% | -2615.5% | Spitzenklasse | |
| ROA (TTM) | -14.1%5-Jahres-Durchschnitt ≈-38.7% | ≈-38.7% | -82.2% | Spitzenklasse | |
| ROE (TTM) | 334.6%5-Jahres-Durchschnitt ≈-105.6% | ≈-105.6% | -72.9% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | HRTX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 2.55-Jahres-Durchschnitt ≈2.6 | ≈2.6 | 3.9 | Geringe Liquidität | |
| Quick Ratio | 1.25-Jahres-Durchschnitt ≈1.2 | ≈1.2 | 3.2 | Geringe Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | HRTX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 7.4%5-Jahres-Durchschnitt ≈12.2% | ≈12.2% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 12.9%5-Jahres-Durchschnitt ≈14.8% | ≈14.8% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 11.8% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | HRTX | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.65-Jahres-Durchschnitt ≈0.5 | ≈0.5 | 0.0 | Spitzenklasse | |
| Inventory Turnover (Lagerumschlag) | 0.65-Jahres-Durchschnitt ≈1.0 | ≈1.0 | · | · | |
| Receivables Turnover (Forderungsumschlag) | 1.85-Jahres-Durchschnitt ≈2.2 | ≈2.2 | · | · | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$1.2M | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
-162.2%
Nächster Bericht
Nov 02, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 11, 2026 | $-0.03 | $0.01 | -394.1% |
| 31. März 2026 | $-0.04 | $-0.02 | -161.4% | |
| 31. Dezember 2025 | $-0.02 | $-0.02 | 2.0% | |
| 30. September 2025 | $-0.04 | $-0.02 | -161.4% | |
| 30. Juni 2025 | $-0.02 | $-0.01 | -96.1% | |
| 31. März 2025 | $0.01 | $-0.01 | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $155M | $144M | $127M | $108M | $86M | $89M | $146M | $77M | $31M | $1M | |
| Cost of Revenue | $41M | $39M | $65M | $55M | $46M | $36M | $62M | $28M | $5M | $35.0K | |
| Gross Profit | $114M | $106M | $62M | $53M | · | · | · | · | · | · | |
| R&D Expense | $12M | $17M | $39M | $83M | $131M | $175M | $167M | $140M | $139M | $103M | |
| SG&A Expense | $55M | $53M | $66M | $62M | $40M | $42M | $38M | $29M | $26M | $21M | |
| Operating Expenses | $116M | $117M | $173M | $227M | $304M | $317M | $357M | $261M | $225M | $172M | |
| Operating Income | $-3M | $-12M | $-111M | $-175M | $-218M | $-228M | $-211M | $-184M | $-195M | $-171M | |
| Interest Expense | · | · | $4M | $2M | $2M | $2M | $1M | $3M | $4M | $3M | |
| Interest Income | $2M | $4M | $3M | $2M | $433.0K | $4M | $7M | $6M | $1M | $445.0K | |
| Other Non-op | $1M | $430.0K | $560.0K | $-7M | $-878.0K | $-847.0K | $158.0K | $2M | $-38.0K | $-9.0K | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-20M | $-14M | $-111M | $-182M | $-221M | $-227M | $-205M | $-179M | $-197M | $-173M | |
| EPS (Basic) | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 | · | · | · | · | · | |
| EPS (Diluted) | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 | · | · | · | · | · | |
| Shares (Basic) | 166,707,000 | 152,449,000 | 138,135,000 | 108,876,000 | 98,471 | · | · | · | · | · | |
| Shares (Diluted) | 166,707,000 | 152,449,000 | 138,135,000 | 108,876,000 | 98,471 | · | · | · | · | · | |
| EBITDA | $-224.0K | $-9M | $-108M | $-172M | $-215M | $-225M | $-209M | $-182M | $-193M | $-171M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $29M | $26M | $29M | $15M | $91M | $105M | $72M | $32M | $145M | $13M | |
| Short-term Investments | · | · | · | · | · | · | · | $301M | $28M | $38M | |
| Receivables | $90M | $79M | $60M | $52M | $35M | $42M | $40M | $65M | $42M | $2M | |
| Inventory | $93M | $53M | $42M | $55M | $48M | $42M | $25M | $39M | $10M | $5M | |
| Prepaid Expense | $9M | $18M | $6M | $14M | $13M | $22M | $23M | $11M | $4M | $4M | |
| Current Assets | $238M | $209M | $189M | $205M | $254M | $314M | $479M | $447M | $228M | $62M | |
| PP&E (Net) | $12M | $15M | $20M | $22M | $24M | $23M | $20M | $15M | $6M | $5M | |
| PP&E (Gross) | $25M | $33M | $37M | $36M | $37M | $34M | $28M | $23M | $14M | $12M | |
| Accum. Depreciation | $13M | $18M | $17M | $14M | $13M | $11M | $8M | $8M | $8M | $7M | |
| Other Non-current Assets | $5M | $6M | $8M | $16M | $18M | $346.0K | $346.0K | $254.0K | $263.0K | $263.0K | |
| Total Assets | $256M | $233M | $223M | $251M | $306M | $354M | $513M | $462M | $234M | $67M | |
| Accounts Payable | $9M | $12M | $3M | $3M | $4M | $525.0K | $3M | $17M | $19M | $7M | |
| Current Liabilities | $96M | $91M | $80M | $82M | $71M | $103M | $97M | $92M | $103M | $39M | |
| Capital Leases | $0 | · | $3M | $5M | $8M | $15M | $12M | · | · | · | |
| Other Non-current Liabilities | $5M | $615.0K | $241.0K | $241.0K | · | · | · | · | · | · | |
| Total Liabilities | $242M | $267M | $256M | $237M | $228M | $117M | $109M | $92M | $103M | $89M | |
| Common Stock | $2M | $2M | $2M | $1M | $1M | $913.0K | $903.0K | $782.0K | $646.0K | $394.0K | |
| Paid-in Capital | $1.95B | $1.88B | $1.87B | $1.81B | $1.69B | $1.63B | $1.57B | $1.33B | $914M | $564M | |
| Retained Earnings | $-1.94B | $-1.92B | $-1.91B | $-1.80B | $-1.61B | $-1.39B | $-1.17B | $-961M | $-783M | $-586M | |
| AOCI | $4.0K | $13.0K | $13.0K | $-19.0K | $-6.0K | $257.0K | $85.0K | $-87.0K | $-10.0K | $-17.0K | |
| Stockholders' Equity | $14M | $-34M | $-34M | $14M | $78M | $236M | $404M | $370M | $131M | $-21M | |
| Liabilities + Equity | $256M | $233M | $223M | $251M | $306M | $354M | $513M | $462M | $234M | $67M | |
| Shares Outstanding | 188,314,430 | 152,127,878 | 150,285,044 | 119,154,538 | 102,005,000 | 91,310,000 | 90,304,000 | 78,174,000 | 64,609,000 | 39,355 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | |
| Stock-based Comp | $10M | $13M | $33M | $43M | $47M | $50M | $51M | $33M | $31M | $26M | |
| Restructuring | · | · | · | · | · | $6M | · | · | · | · | |
| Other Non-cash | $-20M | $-24M | $16M | $-11M | $-33M | $-11M | $27M | $-48M | $-5M | · | |
| Operating Cash Flow | $-28M | $-23M | $-59M | $-147M | $-203M | $-185M | $-125M | $-192M | $-170M | $-134M | |
| CapEx | $317.0K | $2M | $2M | $2M | $3M | $7M | $7M | $9M | $3M | $3M | |
| Investing Cash Flow | $16M | $19M | $18M | $-3M | $33M | $209M | $-22M | $-279M | $8M | $15M | |
| Net Debt Issued | · | · | · | · | · | · | · | $-25M | $-25M | · | |
| Stock Issued | $18M | · | $30M | $75M | · | · | $162M | $363M | $306M | · | |
| Net Stock Activity | $18M | · | $30M | $75M | · | · | $162M | · | · | · | |
| Financing Cash Flow | $14M | $940.0K | $54M | $75M | $156M | $9M | $186M | $358M | $294M | $57M | |
| Net Change in Cash | $3M | $-3M | $13M | $-75M | $-15M | $33M | $40M | $-113M | $131M | $-62M | |
| Free Cash Flow | $-28M | $-24M | $-60M | $-149M | $-206M | $-192M | $-132M | $-201M | $-173M | $-137M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.3% | 73.2% | 48.8% | · | · | · | · | · | · | · | |
| Operating Margin | -1.6% | -8.0% | -87.1% | -162.2% | -252.3% | -257.4% | -144.3% | -237.4% | -632.4% | -13363.2% | |
| Net Margin | -13.0% | -9.4% | -87.0% | -169.0% | -255.6% | -256.4% | -140.3% | -230.8% | -641.9% | -13537.4% | |
| EBITDA Margin | -0.14% | -6.3% | -84.8% | -159.5% | -248.8% | -254.2% | -142.9% | -235.5% | -627.4% | -13363.2% | |
| ROA | -8.3% | -6.0% | -46.7% | -65.4% | -67.0% | -52.5% | -42.0% | -51.3% | -130.9% | -168.7% | |
| ROE | 312.5% | 36.9% | 358.0% | -1010.6% | -224.7% | -88.5% | -59.4% | -46.0% | -359.4% | -357.5% |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | 2.3 | 2.4 | 2.5 | 3.6 | 3.1 | 5.0 | 4.9 | 2.2 | 1.6 | |
| Quick Ratio | 1.2 | 1.1 | 1.1 | 0.8 | 1.8 | 1.4 | 1.2 | 4.3 | 2.1 | 1.4 | |
| Interest Coverage | · | · | -28.6 | -70.6 | -90.4 | -120.0 | -143.1 | -68.8 | -49.4 | -64.2 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.6 | 0.6 | 0.5 | 0.4 | 0.3 | 0.2 | 0.3 | 0.2 | 0.2 | 0.0 | |
| Inventory Turnover | 0.6 | 0.8 | 1.3 | 1.1 | 1.0 | 1.1 | 1.9 | 1.1 | 0.6 | 0.0 | |
| Receivables Turnover | 1.8 | 2.1 | 2.3 | 2.5 | 2.2 | 2.2 | 2.8 | 1.5 | 1.4 | 1.3 |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.08 | $-0.22 | $-0.23 | $0.11 | $0.76 | $2.59 | $4.47 | $4.74 | $2029.69 | $-0.54 | |
| Revenue / Share | $0.93 | $0.95 | $0.92 | $988.94 | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.17 | $-0.15 | $-0.43 | $-1349.35 | · | · | · | · | · | · | |
| Cash / Share | $0.15 | $0.17 | $0.19 | $0.13 | $0.89 | $1.15 | $0.80 | $0.41 | $2237.82 | $0.34 | |
| EPS (TTM) | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 | · | · | · | · | · |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.4% | 13.6% | 18.0% | 24.7% | -2.6% | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.9% | 18.7% | 12.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.8% | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $155M | $144M | $127M | $108M | $86M | $89M | $146M | $77M | $31M | $1M | |
| Net Income TTM | $-20M | $-14M | $-111M | $-182M | $-221M | $-227M | $-205M | $-179M | $-197M | $-173M | |
| Market Cap | $245M | $233M | $255M | $298M | $931M | $1.93B | $2.12B | $2.03B | $1M | $516M | |
| P/E | -10.8 | -17.0 | -2.1 | -1.5 | -4.1 | · | · | · | · | · | |
| P/S | 1.6 | 1.6 | 2.0 | 2.8 | 10.8 | 21.8 | 14.5 | 26.2 | 0.0 | 403.1 | |
| P/B | 17.1 | -6.9 | -7.5 | 21.9 | 12.0 | 8.2 | 5.3 | 5.5 | 0.0 | -24.3 | |
| P / Tangible Book | 17.1 | · | · | 21.9 | 12.0 | 8.2 | · | · | · | · | |
| P / Cash Flow | -8.9 | -10.3 | -4.3 | -2.0 | -4.6 | -10.5 | -17.0 | -10.6 | -0.0 | -3.8 | |
| P / FCF | -8.8 | -9.6 | -4.2 | -2.0 | -4.5 | -10.1 | -16.1 | -10.1 | -0.0 | -3.8 | |
| Earnings Yield | -9.2% | -5.9% | -47.1% | -66.8% | -24.5% | · | · | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38M | $35M | $41M | $38M | $37M | $39M | $41M | $33M | $36M | $35M | $34M | $31M | $32M | $30M | $30M | $27M | |
| Cost of Revenue | $12M | $11M | $11M | $12M | $10M | $8M | $10M | $9M | $11M | $8M | $10M | $18M | $20M | $17M | $13M | $15M | |
| Gross Profit | $26M | $24M | $29M | $26M | $27M | $30M | $31M | $23M | $26M | $26M | $24M | $13M | $12M | $13M | $17M | $12M | |
| R&D Expense | $3M | $2M | $4M | $3M | $3M | $2M | $3M | $4M | $4M | $5M | $8M | $9M | $13M | $9M | $-14M | $26M | |
| SG&A Expense | $11M | $12M | $13M | $14M | $14M | $13M | $12M | $12M | $14M | $15M | $14M | $16M | $20M | $16M | $34M | $10M | |
| Operating Expenses | $28M | $29M | $29M | $30M | $29M | $27M | $26M | $28M | $32M | $31M | $35M | $38M | $54M | $46M | $10M | $54M | |
| Operating Income | $-2M | $-5M | $38.0K | $-4M | $-2M | $3M | $4M | $-4M | $-6M | $-5M | $-10M | $-25M | $-42M | $-33M | $-20M | $-42M | |
| Other Non-op | $-3M | $-3M | $5M | $-2M | $-744.0K | $-519.0K | $2M | $-390.0K | $-3M | $2M | $0 | $-79.0K | $344.0K | $295.0K | $1M | $-26.0K | |
| Net Income | $-5M | $-8M | $-3M | $-17M | $-2M | $3M | $4M | $-5M | $-9M | $-3M | $-11M | $-25M | $-42M | $-33M | $-20M | $-42M | |
| EPS (Basic) | $-0.03 | $-0.04 | $-0.02 | $-0.10 | $-0.02 | $0.02 | $0.02 | $-0.03 | $-0.06 | $-0.02 | $-0.01 | $-0.17 | $-0.35 | $-0.27 | $-0.11 | $-0.38 | |
| EPS (Diluted) | $-0.03 | $-0.04 | $-0.01 | $-0.10 | $-0.02 | $0.01 | $0.02 | $-0.03 | $-0.06 | $-0.02 | $-0.01 | $-0.17 | $-0.35 | $-0.27 | $-0.11 | $-0.38 | |
| Shares (Basic) | 190,335,000 | 189,646,000 | · | 170,348,000 | 154,020,000 | 153,490,000 | · | 152,830,000 | 152,305,000 | 151,199,000 | · | 144,990,000 | 119,719,000 | 119,246,000 | · | 111,735,000 | |
| Shares (Diluted) | 190,335,000 | 189,646,000 | · | 170,348,000 | 154,020,000 | 196,921,000 | · | 152,830,000 | 152,305,000 | 151,199,000 | · | 144,990,000 | 119,719,000 | 119,246,000 | · | 111,735,000 | |
| EBITDA | $-2M | $-4M | · | $-4M | $-2M | $4M | · | $-4M | $-6M | $-4M | · | $-25M | $-42M | $-32M | · | $-42M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $21M | $26M | $29M | $43M | $17M | $19M | $26M | $26M | $18M | $20M | · | $35M | $13M | $27M | · | $50M | |
| Receivables | $90M | $84M | $90M | $81M | $80M | $79M | $79M | $67M | $74M | $65M | · | $64M | $77M | $51M | · | $42M | |
| Inventory | $91M | $93M | $93M | $70M | $73M | $57M | $53M | $46M | $43M | $42M | · | $42M | $45M | $52M | · | $52M | |
| Prepaid Expense | $7M | $8M | $9M | $23M | $17M | $26M | $18M | $11M | $7M | $7M | · | $11M | $11M | $15M | · | $8M | |
| Current Assets | $230M | $229M | $238M | $229M | $211M | $213M | $209M | $195M | $191M | $186M | · | $194M | $165M | $178M | · | $224M | |
| PP&E (Net) | $12M | $12M | $12M | $13M | $14M | $15M | $15M | $15M | $16M | $19M | · | $21M | $21M | $22M | · | $23M | |
| PP&E (Gross) | · | · | $25M | · | · | · | $33M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $13M | · | · | · | $18M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $7M | $7M | $8M | · | $8M | $9M | $14M | · | $17M | |
| Total Assets | $252M | $246M | $256M | $249M | $232M | $236M | $233M | $221M | $218M | $218M | · | $229M | $201M | $221M | · | $272M | |
| Accounts Payable | $12M | $9M | $9M | $12M | $12M | $12M | $12M | $10M | $10M | $837.0K | · | $2M | $2M | $4M | · | $7M | |
| Current Liabilities | $92M | $91M | $96M | $90M | $259M | $89M | $91M | $86M | $80M | $75M | · | $80M | $87M | $78M | · | $94M | |
| Capital Leases | $6M | · | · | · | · | · | · | $522.0K | $1M | $2M | · | $4M | $4M | $5M | · | $6M | |
| Other Non-current Liabilities | $5M | $5M | $5M | $5M | $747.0K | $682.0K | $615.0K | $241.0K | $241.0K | $241.0K | · | $241.0K | $241.0K | $241.0K | · | $241.0K | |
| Total Liabilities | $245M | $237M | $242M | $234M | $259M | $264M | $267M | $261M | $256M | $252M | · | $257M | $241M | $232M | · | $250M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $1M | $1M | $1M | · | $1M | |
| Paid-in Capital | $1.96B | $1.95B | $1.95B | $1.94B | $1.89B | $1.89B | $1.88B | $1.88B | $1.88B | $1.87B | · | $1.87B | $1.83B | $1.82B | · | $1.80B | |
| Retained Earnings | $-1.95B | $-1.95B | $-1.94B | $-1.94B | $-1.92B | $-1.92B | $-1.92B | $-1.92B | $-1.92B | $-1.91B | · | $-1.90B | $-1.87B | $-1.83B | · | $-1.78B | |
| AOCI | $-6.0K | $-6.0K | $4.0K | $0 | $-1.0K | $1.0K | $13.0K | $40.0K | $-8.0K | $-6.0K | · | $-1.0K | $-6.0K | $9.0K | · | $-57.0K | |
| Stockholders' Equity | $7M | $9M | $14M | $15M | $-27M | $-28M | $-34M | $-40M | $-38M | $-34M | $-34M | $-28M | $-39M | $-11M | $14M | $22M | |
| Liabilities + Equity | $252M | $246M | $256M | $249M | $232M | $236M | $233M | $221M | $218M | $218M | · | $229M | $201M | $221M | · | $272M | |
| Shares Outstanding | · | · | 188,314,430 | · | · | · | 152,127,878 | · | · | · | · | · | · | · | · | · |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $452.0K | $529.0K | $537.0K | $615.0K | $611.0K | $551.0K | $581.0K | $581.0K | $641.0K | $689.0K | $715.0K | $727.0K | $739.0K | $718.0K | $791.0K | $706.0K | |
| Stock-based Comp | $3M | $3M | $2M | $3M | $3M | $3M | $2M | $3M | $5M | $3M | $4M | $7M | $14M | $8M | $11M | $11M | |
| Other Non-cash | · | $3M | · | · | · | $-15M | · | · | · | $-10M | · | · | · | $-797.0K | · | · | |
| Operating Cash Flow | $-2M | $-2M | $-9M | $1M | $-11M | $-9M | $-12M | $3M | $-5M | $-10M | $2M | $-9M | $-27M | $-25M | $-38M | $-37M | |
| CapEx | $138.0K | $391.0K | $0 | $0 | $208.0K | $109.0K | $638.0K | $431.0K | · | · | $250.0K | $793.0K | $278.0K | $224.0K | $414.0K | $45.0K | |
| Investing Cash Flow | $-3M | $-939.0K | $-5M | $12M | $7M | $2M | $11M | $4M | $2M | $1M | $-9M | $-23M | $13M | $37M | $2M | $-36M | |
| Stock Issued | · | · | $-2M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $82.0K | $-51.0K | $219.0K | $13M | $781.0K | $64.0K | $423.0K | $14.0K | $492.0K | $11.0K | $199.0K | $54M | $319.0K | $-208.0K | $439.0K | $75M | |
| Net Change in Cash | $-5M | $-3M | $-14M | $27M | $-3M | $-7M | $61.0K | $7M | $-2M | $-8M | $-6M | $21M | $-14M | $12M | $-35M | $2M | |
| Free Cash Flow | · | $-2M | · | · | · | $-9M | · | · | · | · | · | · | · | $-25M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.3% | 69.3% | · | 68.8% | 73.5% | 78.3% | · | 71.2% | 70.8% | 75.6% | · | 42.1% | · | · | · | · | |
| Operating Margin | -5.4% | -13.7% | · | -10.7% | -4.4% | 8.1% | · | -13.6% | -17.9% | -13.8% | · | -79.3% | -133.5% | -111.6% | · | -157.7% | |
| Net Margin | -14.6% | -23.4% | · | -45.8% | -6.4% | 6.8% | · | -14.8% | -25.6% | -9.1% | · | -79.6% | -132.4% | -110.7% | · | -157.8% | |
| EBITDA Margin | -5.4% | -12.2% | · | -10.7% | -4.4% | 9.5% | · | -13.6% | -17.9% | -11.8% | · | -79.3% | -133.5% | -109.2% | · | -157.7% | |
| ROA | -2.3% | -3.4% | · | -7.4% | -1.1% | 1.2% | · | -2.1% | -4.4% | -1.4% | · | -10.0% | -18.9% | -13.2% | · | -13.4% | |
| ROE | 53.9% | 84.0% | · | 139.3% | 7.3% | -8.5% | · | 14.3% | 23.9% | 14.0% | · | 937.3% | 137.8% | -523.1% | · | -59.3% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | 2.5 | · | 2.6 | 0.8 | 2.4 | · | 2.3 | 2.4 | 2.5 | · | 2.4 | 1.9 | 2.3 | · | 2.4 | |
| Quick Ratio | 1.2 | 1.2 | · | 1.4 | 0.4 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | 1.0 | 1.0 | · | 1.0 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | · | 0.2 | 0.2 | 0.2 | · | 0.1 | 0.2 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.1 | 0.1 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.4 | 0.4 | 0.3 | · | 0.3 | |
| Receivables Turnover | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.5 | · | 0.5 | 0.5 | 0.6 | · | 0.6 | 0.5 | 0.6 | · | 0.6 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $0.20 | $0.18 | · | $0.22 | $0.24 | $0.20 | · | $0.21 | $0.24 | $0.23 | · | $0.22 | $0.27 | $0.25 | · | $0.24 | |
| Cash Flow / Share | · | $-0.01 | · | · | · | $-0.04 | · | · | · | $-0.06 | · | · | · | $-0.21 | · | · | |
| EPS (TTM) | $-0.18 | $-0.17 | · | $-0.09 | $-0.02 | $-0.06 | · | $-0.12 | $-0.26 | $-0.55 | · | $-0.90 | $-1.11 | $-1.31 | · | $-2.09 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $151M | $151M | · | $155M | $150M | $149M | · | $138M | $136M | $132M | · | $123M | $118M | $114M | · | $98M | |
| Net Income TTM | $-34M | $-31M | · | $-14M | $-931.0K | $-8M | · | $-28M | $-48M | $-81M | · | $-120M | $-137M | $-151M | · | $-217M | |
| P/E | -2.4 | -4.7 | · | -14.0 | -103.5 | -36.7 | · | -16.6 | -13.5 | -5.0 | · | -1.1 | -1.0 | -1.2 | · | -2.0 | |
| Earnings Yield | -41.9% | -21.2% | · | -7.1% | -0.97% | -2.7% | · | -6.0% | -7.4% | -19.9% | · | -87.4% | -95.7% | -86.8% | · | -49.5% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $155M | $144M | $127M | $108M | $86M |
| Bruttogewinnmarge % | 73.3% | 73.2% | 48.8% | · | · |
| Betriebsgewinnmarge % | -1.6% | -8.0% | -87.1% | -162.2% | -252.3% |
| Nettoergebnis | $-20M | $-14M | $-111M | $-182M | $-221M |
| Verwässerte EPS | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 2.5 | 2.3 | 2.4 | 2.5 | 3.6 |
| Quick Ratio | 1.2 | 1.1 | 1.1 | 0.8 | 1.8 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-28M | $-24M | $-60M | $-149M | $-206M |
Institutionelle Eigentümer (13F) 182 Einreicher · $72.8M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
182
Gehaltener Wert
$72.8M
Neue Positionen
22
Geschlossene Positionen
21
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 22 (-15 vs. Vorquartal) | 21 (-6 vs. Vorquartal) | 58 (+7 vs. Vorquartal) | 42 (-2 vs. Vorquartal) | -23.0M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Rubric Capital Management LP | $12.823.986 | 30.046.828 | 17,60% | Aktien |
| VANGUARD GROUP INC | $12.766.499 | 9.820.384 | 17,53% | Aktien |
| Clearline Capital LP | $4.858.675 | 11.383.961 | 6,67% | Aktien |
| BlackRock, Inc. | $4.503.060 | 10.550.750 | 6,18% | Aktien |
| Velan Capital Investment Management LP | $3.735.904 | 8.753.290 | 5,13% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.323.230 | 7.782.741 | 4,56% | Aktien |
| Tejara Capital Ltd | $2.778.807 | 6.510.795 | 3,81% | Aktien |
| TANG CAPITAL MANAGEMENT LLC | $2.667.500 | 6.250.000 | 3,66% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $1.823.405 | 4.270.980 | 2,50% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $1.737.119 | 4.070.101 | 2,38% | Aktien |
| JW Asset Management, LLC | $1.600.958 | 3.751.073 | 2,20% | Aktien |
| Stonepine Capital Management, LLC | $1.500.000 | 1.000.000 | 2,06% | Kaufoption |
| STATE STREET CORP | $1.377.948 | 3.228.557 | 1,89% | Aktien |
| UBS Group AG | $1.279.750 | 2.997.073 | 1,76% | Aktien |
| Pale Fire Capital SE | $1.071.899 | 2.511.478 | 1,47% | Aktien |
| MARSHALL WACE, LLP | $1.012.302 | 2.354.193 | 1,39% | Aktien |
| Caption Management, LLC | $896.280 | 2.100.000 | 1,23% | Verkaufsoption |
| Congress Park Capital LLC | $860.620 | 2.016.447 | 1,18% | Aktien |
| Richmond Brothers, Inc. | $764.961 | 1.792.319 | 1,05% | Aktien |
| TWO SIGMA ADVISERS, LP | $675.442 | 519.571 | 0,93% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $674.878 | 1.580.510 | 0,93% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $663.186 | 1.553.857 | 0,91% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $643.145 | 1.506.900 | 0,88% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $582.906 | 1.365.119 | 0,80% | Aktien |
| GOLDMAN SACHS GROUP INC | $567.539 | 1.329.754 | 0,78% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $547.071 | 1.281.796 | 0,75% | Aktien |
| NORTHERN TRUST CORP | $522.181 | 1.223.480 | 0,72% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $519.613 | 1.217.463 | 0,71% | Aktien |
| Qube Research & Technologies Ltd | $435.802 | 1.021.092 | 0,60% | Aktien |
| Caption Management, LLC | $426.800 | 1.000.000 | 0,59% | Aktien |
| CM Management, LLC | $426.800 | 1.000.000 | 0,59% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $296.270 | 694.165 | 0,41% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $239.958 | 299.910 | 0,33% | Aktien |
| Stonepine Capital Management, LLC | $209.468 | 490.787 | 0,29% | Aktien |
| NEXPOINT ASSET MANAGEMENT, L.P. | $203.050 | 475.750 | 0,28% | Aktien |
| DIADEMA PARTNERS LP | $195.783 | 458.723 | 0,27% | Aktien |
| Invesco Ltd. | $173.565 | 406.668 | 0,24% | Aktien |
| Xcelsior Advisor Partners LLC | $173.186 | 405.777 | 0,24% | Aktien |
| Bank of New York Mellon Corp | $168.944 | 395.838 | 0,23% | Aktien |
| Apeiron RIA LLC | $158.163 | 370.579 | 0,22% | Aktien |
| Squarepoint Ops LLC | $137.078 | 321.177 | 0,19% | Aktien |
| Glenmede Investment Management, LP | $132.710 | 105.326 | 0,18% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $113.663 | 266.314 | 0,16% | Aktien |
| FMR LLC | $96.800 | 226.803 | 0,13% | Aktien |
| Nuveen, LLC | $94.659 | 221.787 | 0,13% | Aktien |
| Abel Hall, LLC | $90.987 | 213.185 | 0,12% | Aktien |
| CAROLINAS WEALTH CONSULTING LLC | $90.983 | 41.356 | 0,12% | Aktien |
| Horan Securities, Inc. | $86.091 | 41.590 | 0,12% | Aktien |
| RHUMBLINE ADVISERS | $83.482 | 195.537 | 0,11% | Aktien |
| Cutter & CO Brokerage, Inc. | $80.223 | 36.465 | 0,11% | Aktien |
Aktivisten & 5%+-Eigentümer 3 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Rubric Capital Management LP, David Rosen ×6 Einreichungen | 17. Oktober 2025 | 15,90% | Änderung | · | SEC |
| Tang Capital Partners, LP, Tang Capital Management, LLC, Kevin Tang ×20 Einreichungen | 7. Januar 2020 | · | Erste Einreichung | · | SEC |
| Felix J. Baker, Julian C. Baker ×3 Einreichungen | 7. Juli 2011 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 40 Insider · 21 Führungskräfte · 21 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Craig A Collard | Chief Executive Officer | 31. Juli 2026 M | 856.492 | 0 | 0 | $0 |
| Barry D Quart | Chief Executive Officer | 18. Januar 2023 A | 177.989 | 0 | 0 | $0 |
| Ronald J Prentki | President & CEO | 17. Februar 2010 A | 40.539 | 0 | 0 | $0 |
| Michael Oconnell | Chief Executive Officer | 10. Januar 2006 A | 132.200 | 0 | 0 | $0 |
| Ira Duarte | EVP, Chief Financial Officer | 31. Juli 2026 M | 281.899 | 0 | 0 | $0 |
| Robert Hoffman | CFO & SVP, Finance | 19. Dezember 2019 A | 1.280 | 0 | 0 | $0 |
| Brian G. Drazba | VP, Finance & CFO | 31. Oktober 2016 J | 3.798 | 0 | 0 | $0 |
| John Whelan | CFO | 18. Juli 2013 M | 254.088 | 0 | 0 | $0 |
| Stephen Whiteford | V.P., Finance & CFO | 15. Dezember 2006 A | 15.000 | 0 | 0 | $0 |
| John Poyhonen | President & CCO | 13. April 2023 M | 46.648 | 0 | 0 | $0 |
| Robert Rosen | President | 15. Dezember 2018 A | 2.640 | 0 | 0 | $0 |
| David Leslie Szekeres | EVP, Chief Operating Officer | 13. Juli 2023 M | 33.754 | 0 | 0 | $0 |
| Michael A Adam | Chief Operating Officer | 8. Februar 2013 A | · | 0 | 0 | $0 |
| William P Forbes | EVP, Chief Development Officer | 31. Juli 2026 M | 241.173 | 0 | 0 | $0 |
| Lisa Peraza | VP, Chief Accounting Officer | 19. Januar 2024 A | 55.907 | 0 | 0 | $0 |
| Kimberly Manhard | EVP, Drug Development | 13. April 2023 M | 28.330 | 0 | 0 | $0 |
| Marshall Paul | SVP, Technical Operations | 21. März 2016 M | 2.200 | 0 | 0 | $0 |
| Neil James Clendeninn | SVP & Chief Medical Officer | 12. Oktober 2015 A | · | 0 | 0 | $0 |
| Mark S. Gelder MD | SVP & Chief Medical Officer | 12. Dezember 2014 A | · | 0 | 0 | $0 |
| John Barr | Vice President of R&D | 8. Juli 2011 A | 51.772 | 0 | 0 | $0 |
| Anastassios D. Retzios | VP of Clinical Development | 15. Januar 2008 A | · | 0 | 0 | $0 |
| Thomas Cusack | Direktor | 30. Januar 2026 A | 53.960 | 0 | 0 | $0 |
| Morgan Adam | Direktor | 30. Januar 2026 A | 123.737 | 0 | 0 | $0 |
| Sharmila Dissanaike | Direktor | 30. Januar 2026 A | 53.960 | 0 | 0 | $0 |
| Michael Kaseta | Direktor | 30. Januar 2026 A | 53.960 | 0 | 0 | $0 |
| Waage Christian | Direktor | 30. Januar 2026 A | 53.960 | 0 | 0 | $0 |
| Craig A Johnson | Direktor | 30. Januar 2026 A | 53.960 | 0 | 0 | $0 |
| Susan Rodriguez | Direktor | 31. Januar 2025 A | 87.180 | 0 | 0 | $0 |
| Stephen Davis | Direktor | 16. Dezember 2022 A | 52.032 | 0 | 0 | $0 |
| KEVIN TANG | Direktor | 19. Dezember 2019 A | 5.799.810 | 0 | 0 | $0 |
| Greg Turnbull | Direktor | 29. Mai 2012 A | 245.092 | 0 | 0 | $0 |
| Paul Goddard | Direktor | 29. Mai 2012 A | 214.683 | 0 | 0 | $0 |
| Toby Rosenblatt | Direktor | 20. Mai 2010 A | 210.234 | 0 | 0 | $0 |
| Robert L Zerbe MD | Direktor | 20. Mai 2010 A | 202.072 | 0 | 0 | $0 |
| Peter Riepenhausen | Direktor | 28. Mai 2008 A | 9.000 | 0 | 0 | $0 |
| Arthur T Taylor | Direktor | 28. Mai 2008 A | 12.000 | 0 | 0 | $0 |
| Dennis L Winger | Direktor | 11. August 2006 A | 69.544 | 0 | 0 | $0 |
| Stephen A Drury | Direktor | 11. August 2006 J | 83.283 | 0 | 0 | $0 |
| SPCH, LLLP | 10%-Eigentümer | 1. Januar 2013 J | 0 | 0 | 0 | $0 |
| Mark Earl Hensley | · | 6. August 2026 M | 170.901 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 15 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,59% | 376.931 SH | 2. Oktober 2026 | Täglich |
| IWC · iShares Trust | 0,01% | 533.800 SH | 11. September 2026 | Täglich |
| IWO · iShares Trust | 0,00% | 1.361.330 SH | 11. September 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,00% | 195.097 SH | 2. Oktober 2026 | Täglich |
| RSSL · Global X Funds | 0,00% | 76.332 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,00% | 3.617.230 SH | 11. September 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 2.063.361 SH | 19. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5.474.947 SH | 19. August 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,00% | 925.988 SH | 19. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,00% | 13.208 SH | 19. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 156.616 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 12.513 SH | 19. August 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 28.936 SH | 3. September 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,00% | 472.185 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 507.316 SH | 11. September 2026 | Täglich |
HRTX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 7 Analysten
VERKAUF
Median-Ziel
$7.00
+1913,8%
0 0,0%
Starker Kauf
0 0,0%
Kauf
4 57,1%
Halten
1 14,3%
Verkauf
2 28,6%
Starker Verkauf
12-Monats-Kursziel
3 Analysten · 2026-10-01Mittelwert-Ziel $7.00 +1913,8%
← Unter allen Zielen
Aktueller Preis $0.35
Tief$5.00
Mittelwert$7.00
Hoch$9.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| HRTX | $245M | -10.8 | 7.4% | -13.0% | 312.5% | 73.3% |
| GANX | $135M | -5.3 | -60.6% | · | -181.1% | · |
| TENX | $114M | -9.1 | · | · | -52.5% | · |
| ALDX | $312M | -9.2 | · | · | -68.0% | · |
| RNXT | · | -2.6 | 2511.6% | · | · | · |
| SPRO | $131M | 15.5 | 39.2% | 12.8% | 18.7% | · |
| GRML | · | · | · | · | -104.9% | · |
| RNTX | · | -0.6 | · | · | · | · |
| XBIT | · | -1.6 | · | · | · | · |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 10, 2026